Aridis Pharmaceuticals Inc expected to post a loss of 41  cents a share - Earnings Preview

Aridis Pharmaceuticals

25/03/2022 22:36

* Aridis Pharmaceuticals Inc  ARDS.OQ   ARDS.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 28 (estimated). 
    * The Los Gatos California-based  company is expected to
report
revenue of $1.9 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Aridis
Pharmaceuticals
Inc is for a loss of 41 cents per share. For the same quarter
last year, the company reported a loss of 59 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $14​, above​ its last closing price
of $1.65. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.51       -0.51      -1.94     Missed  -277.9
 Jun. 30 2021  -0.64       -0.63      -0.55     Beat    12.4
 Mar. 31 2021  -0.61       -0.62      -0.77     Missed  -24.7​
 Dec. 31 2020              -0.59      -0.59     Met     0.6
 ​​Sep.        -0.64       -0.63      -0.65     Missed  -3.5
 30 2020                                                
 Jun. 30 2020  -0.74       -0.74      -0.47     Beat    36.8​
 Mar. 31 2020  -0.66       -0.67      -0.73     Missed  -9
 Dec. 31 2019  -0.77       -0.81      -0.63     Beat    22
 This summary was machine generated March 25 at 22:36 GMT.  All
figures in US dollars  unless otherwise stated